摘要
目的统计维持性血液透析患者抗失眠药物应用情况,对比分析不同药物的有效性及安全性,以促进临床安全合理用药。方法回顾性分析2019年1月至2020年6月接受抗失眠药物治疗的维持性血液透析患者82例,依服用抗失眠药物不同分为唑吡坦组及艾司唑仑组,比较分析组间服用相应抗失眠药物治疗期间相关指标与停药后相关指标。结果唑吡坦组服药后平均入睡时间为(22.68±5.06)min,显著短于艾司唑仑组的(44.33±8.97)min(P<0.05),平均睡眠时间为(8.16±1.37)h,较艾司唑仑组的(6.96±0.82)h显著延长(P<0.05);唑吡坦组服药后PSQI平均得分为(10.00±2.49)分,显著低于艾司唑仑组的(13.18±1.68)min(P<0.05);与艾司唑仑组比较,唑吡坦组存在较高的顺行性遗忘发生率(40.54%vs 17.78%,P<0.05),但头痛(13.51%vs 33.33%)、药物耐药(29.73%vs 71.11%)、幻觉(13.51%vs 33.33%)、共济失调(5.41%vs 31.11%)、呼吸抑制(0 vs 13.33%)发生率显著优于艾司唑仑组(P<0.05);停药后唑吡坦组失眠加重、焦虑及药物依赖的发生率显著低于艾司唑仑组(32.43%vs 57.78%、8.11%vs 53.33%、10.81%vs 60.00%,P<0.05)。结论唑吡坦在维持性血液透析患者抗失眠治疗中具有显著的有效性及高度安全性,值得临床广泛应用。
Objective To analyze the effectiveness and safety of different drugs in patients undergoing maintenance hemodialysis.Methods Eighty-two patients who were treated by maintenance hemodialysis in our hospital from January 2019 to June 2020 were enrolled in the study,who were divided into zolpidem treatment group and estazolam treatment group.The related indexes during and after treatment were observed and compared between the two groups.Results The mean time to fall asleep in zolpidem treatment group was significantly shorter than that in astazolam treatment group,however,the mean sleep time was significantly longer than that in astazolam treatment group(P<0.05).The mean PSQI scores in zolpidem group were significantly lower than those in astazolam group(P<0.05).Moreover,the incidence rate in zolpidem group treatment was significantly higher than that in estazolam group(P<0.05).And the incidences rates of headache,drug resistance,hallucinations,ataxia and respiratory depression in zolpidem treatment group were significantly lower than those in estazolam treatment group(P<0.05).Conclusion Zolpidem is highly effective and safe in treating patients with maintenance hemodialysis,which is worthy of clinical application and promotion.
作者
李田军
LI Tianjun(Xuancheng People’s Hospital,Anhui,Xuancheng 242000,China)
出处
《河北医药》
CAS
2022年第3期378-380,384,共4页
Hebei Medical Journal
基金
吴阶平医学会科研专项基金课题(编号:320.6750.19090-18)。
